key: cord-0728440-9i94r49g
authors: Gu, Maggie; Torres, Jonathan L.; Greenhouse, Jack; Wallace, Shannon; Chiang, Chi-I; Jackson, Abigail M.; Porto, Maciel; Kar, Swagata; Li, Yuxing; Ward, Andrew B.; Wang, Yimeng
title: One dose of COVID-19 nanoparticle vaccine REVC-128 provides protection against SARS-CoV-2 challenge at two weeks post immunization
date: 2021-04-02
journal: bioRxiv
DOI: 10.1101/2021.04.02.438218
sha: 656b781044c0a46689abaa84613dbefe2dbca087
doc_id: 728440
cord_uid: 9i94r49g

A COVID-19 vaccine with capability to induce early protection is needed to efficiently eliminate viral spread. Here, we demonstrate the development of a nanoparticle vaccine candidate, REVC-128, in which multiple trimeric spike ectodomain subunits with glycine (G) at position 614 were multimerized onto a nanoparticle. In-vitro characterization of this vaccine confirms its structural and antigenic integrity. In-vivo immunogenicity evaluation in mice indicates that a single dose of this vaccine induces potent serum neutralizing antibody titer at two weeks post immunization, which is significantly higher than titer induced by trimeric spike protein without nanoparticle presentation. The comparison of serum binding to spike subunits between animals immunized by spike with and without nanoparticle presentation indicates that nanoparticle prefers the display of spike RBD (Receptor-Binding Domain) over S2 subunit, likely resulting in a more neutralizing but less cross-reactive antibody response. Moreover, a Syrian golden hamster in-vivo model for SARS-CoV-2 virus challenge was implemented at two weeks post a single dose of REVC-128 immunization. The results show that vaccination protects hamsters against SARS-CoV-2 virus challenge with evidence of steady body weight, suppressed viral loads and alleviation of tissue damage (lung and nares) for protected animals, compared with ~10% weight loss, higher viral loads and tissue damage in unprotected animals. Furthermore, the data show that vaccine REVC-128 is thermostable at up to 37°C for at least 4 weeks. These findings, along with a long history of safety for protein vaccines, suggest that the REVC-128 is a safe, stable and efficacious single-shot vaccine candidate to induce the earliest protection against SARS-CoV-2 infection.

by ELISA and BLI (Fig. 2) confirmed that spike NP and non-NP all displayed the favorable 131 epitopes targeted by the tested nAbs. 132

Spike NP was initially stored at -80°C. To understand the stability of spike NP stored at 133 different temperatures, we evaluated the conformational integrity and antigenicity of this protein 134 when stored at 4°C, 22°C (room temperature, RT), and 37°C for a period of 2 days, 1 week and 4 135 weeks. Three representative antibodies targeting the RBD, NTD and S2 subunits of SARS-CoV-2 136 spike protein, and a negative control antibody were used to test binding. As shown in Fig. S1 , spike 137 NP stored at different temperatures for up to 4 weeks displayed binding to selected RBD and NTD-138 specific antibodies-CB6 and 4A8 9,31 respectively, identical to positive control spike NP protein 139 stored at -80°C, although we observed slightly decreased binding to the S2 subunit-specific 140 antibody, RV82. RV82 is a fully human monoclonal antibody (IgG1) that was identified from a B 141 cell repertoire of COVID-19 convalescent human and confirmed to bind to monomeric or trimeric 142 S2 subunit proteins of SARS-CoV-2 (Fig. S2A) . Consistently, RV82 retained binding to trimeric 143 spike protein of SARS-CoV-2 B.1.351 variant (initially identified in the South Africa) that has all 144 mutations located within S1 subunit, while most of tested RBD-or NTD-specific antibodies 145

showed ablated binding to these mutations, with the exception of CR3022 32 and COVA1-16 4 146 antibodies (Left two, Fig. S2B ). Different from CR3022 and COVA1-16, RV82 bound to SARS-147

CoV-2, but not SARS (2003 strain) (Right, Fig. S2B ). Together with the notion that RBD and 148 NTD are the major neutralizing epitopes 4,5,9,31 , and SDS-PAGE analysis of spike NP showed no 149 difference between protein being stored at various temperatures and -80°C (data not shown), we 150 suggest that spike NP is stable up to 37°C for at least 4 weeks. In the future, other methods to 151 verify the thermostability, such as EM and DSF (Differential Scanning Fluorimetry), will be 152 utilized.

We next evaluated the immunogenicity of 154 spike NP and non-NP in mice. Two groups of mice were immunized with spike NP and spike non-155 NP with the Sigma Adjuvant System via subcutaneous injection route, respectively. A third group 156 of mice were injected with PBS as a negative control. We first assessed antibody binding of sera 157 collected 14-or 28-days post immunization to trimeric spike protein with D614G mutation. 158

Significant levels of spike protein-specific IgG were detected in all vaccinated mice 14 days post 159 immunization and spike NP induced spike-specific IgG ~1.5-fold higher than spike non-NP on 160 days 14 and 28, with the titer declining on day 28 (Fig. 3A) . Besides trimeric spike protein binding, 161

we assessed the binding of RBD, S2, and NTD subunits to sera collected 14 days post 162

immunization. The results showed that sera from spike NP immunized mice displayed significantly 163 higher binding to RBD than sera from spike non-NP immunized animals (** p<0.01, Whitney test) (Left, Fig. 3B ), while serum binding to S2 subunit was opposite, with sera from 165 spike non-NP immunized animals showing significantly stronger binding to S2 subunit (** p<0.01, 166

Mann-Whitney test) (Middle, Fig. 3B ), indicating NP presentation preferentially exposed RBD 167 over S2 subunit, consistent with vaccine design. NTD-specific antibody responses in all groups 168 were weak on day 14 (Right, Fig. 3B ). 169

Cross-reactive and non or weak neutralizing antibodies are potentially responsible for 170 antibody-dependent enhancement (ADE). To evaluate vaccine-elicited cross-reactive antibodies, 171

we assessed sera collected on day 14 for binding to trimeric spike proteins from SARS (2003 172 strain) or MERS. Consistent with S2 subunit binding, sera from spike non-NP immunized animals 173 showed stronger binding to these two different coronavirus spike proteins than sera from spike NP 174 immunized ones, especially to the MERS spike protein (* p<0.05, Mann-Whitney test) (Fig. 3C) .

The data suggested spike NP elicited less cross-reactive antibodies that are possibly S2 subunit-176

Neutralizing antibodies are related to vaccine-induced protection. Sera collected on days 178 14 and 28 were tested for their neutralizing antibody activity against VSV pseudotyped virus with 179 SARS-CoV-2 spike protein containing D614G mutation and a luciferase reporter. On day 14, we 180 observed that the neutralizing antibody (nAb) titer of sera from spike NP immunized mice was on 181 average 4 log (ID50), significantly higher than the titer of sera from spike non-NP immunized ones 182 Fig. 3D ). Similarly, the neutralizing antibody titer declined 183 on day 28, but the titer of spike NP immunized sera was still significantly higher than that of spike 184 non-NP immunized sera (* p<0.05, Mann-Whitney test) (Right, Fig. 3D ). To assess neutralizing 185 antibody epitope on spike protein, we analyzed the correlation between day 14 serum neutralizing 186 titer and ELISA titer obtained from either binding to spike RBD subunit or whole spike protein. This analysis revealed a more correlated relationship between neutralizing titer and RBD binding 188 titer (R=0.6915, *** p=0.0007), compared to the correlate with spike binding (R=0.4537, * 189 p=0.045) (Fig. 3E) , indicating RBD is the major neutralizing antibody epitope and RBD-specific 190 nAbs are responsible for serum neutralizing activity. This is in agreement with the rationale of our 191 vaccine design by using NP to preferentially present RBD, validated by the above BLI results (Fig.  192 

Protection efficacy of spike NP in hamsters. Encouraged by the potent immune mouse serum 194 neutralizing antibody response elicited by spike NP that we observed on day 14, we next evaluated 195 vaccine protection efficacy in Syrian golden hamsters, one of few small animal models susceptible 196 to infection by the SARS-CoV-2 virus 33,34 . Two groups of hamsters were immunized with a single 197 dose of spike NP (REVC-128) or sham control including same NP presenting Marburg trimeric from spike NP immunized hamsters on day 13, one day prior to virus challenge, displayed 200 significantly higher potent neutralizing antibody activity against VSV pseudotyped with SARS-201

CoV-2 D614G spike than sera from the sham group (* p<0.05, Mann-Whitney test) (Fig. 4B) . 202

Fourteen days post immunization, animals were challenged with SARS-CoV-2 virus 203 intranasally. In the sham control, hamsters lost a median of 10% body weight by 7 days post 204 infection (dpi), while spike NP immunized animals gained body weight lightly from 4 dpi ( Table 1 ). Perivascular 221 edema (grade 1 or 2), syncytial cells and hemorrhage (grade 1) were observed in lungs of some 222 but not all animals in the sham control ( Fig. 4F and Table 1 ). The majority of animals in the sham 223 control also exhibited atypia of hyperplastic alveolar epithelial cells with hypertrophic and variably 224 shaped nuclei and prominent nucleoli (Fig. 4E ). Syncytial cells, enlarged multinucleated cells, Protein-based vaccines, such as the Hepatitis B vaccine that has been administered on the first day 241 of life for newborn babies, have shown minimal safety concern. The backbone of the nanoparticle, 242 ferritin, has also been shown to be safe for influenza vaccines in clinical trials. Therefore, REVC-243 128 has the potential to protect individuals who are medically unable to receive other COVID-19 244 vaccines, such as people who are allergic to mRNA vaccines. Additionally, the vaccine stability 245 data (Fig. S1 ) support a much less stringent requirement for the storage of this vaccine, compared 246 with mRNA vaccines that require -20°C or -80°C storage. Vaccine storage and transportation in 247 ambient temperature condition will enable broader availability of such vaccine. 248

Vaccination using a one-dose regimen enables easier deployment, tracking and 249 administration, compared to a two-dose regimen. Further, vaccine with the capability to induce 250 early protection can more efficiently prevent viral spread and contribute to the quelling of this 251 COVID-19 pandemic. Herein, we showed that a single dose of REVC-128 provides protection 252 starting two weeks post immunization, earlier than other vaccine candidates. To our knowledge, 253 two viral vector vaccines (VSV and Ad26) have been reported to induce early protection starting 254 four weeks post immunization using a one-dose regimen 33,40 , while mRNA vaccines (e.g., 255

Moderna, Pfizer/BioNTech), inactivated vaccine (e.g., Sinovac Life Sciences) and another 256 nanoparticle protein vaccine, Novavax's NVX-CoV2373 that all use a two-dose regimen with 257 evidence of protection occurring at or after four weeks post the first dose of immunization. 258

Although viral vector vaccines induced early protection, the preexisting immunity to viral vectors 259 presents a formidable challenge for this platform, especially when a boosting immunization is 260 required. The booster enhances the immune response to viral vector, which could impair vector 261 entry into host cells. In contrast, protein or mRNA vaccines avoid this challenge and allow more 262 flexibility for multiple boosts to achieve a longer protection period or protection against mutant 263 variants. We observed the decreased neutralizing antibody titer on day 28 after a single dose of 264 immunization (Fig. 3D) , and also observed the enhanced titer following a booster (data not shown). 265

The protection durability induced by both one-dose and two-dose regimens merits further 266 investigation. The immunogen dose used in this report is high (20 μg per mouse or 100 μg per 267 hamster), warranting a dose-deescalating study to assess the optimal dose in the future. containing fusion machinery exhibits a higher degree of homology among coronaviruses than the 284 S1 subunit of spike protein. It has been reported that antibodies from SARS-CoV-2 naïve donors 285 who had reactivity to seasonal human coronavirus strains (such as OC43 and HKU1) were cross-286 reactive against the nucleocapsid and S2 subunit on spike protein of SARS-CoV-2 50 . More studies 287 have reported that cross-reactive mAbs largely target this more conserved S2 subunit on spike 288 protein 51,52 . Conceptually, a number of S2 subunit-specific antibodies is non or weakly neutralizing, and potentially responsible for ADE. Thus, vaccine design to minimize the elicitation 290 of S2 subunit-specific antibodies should be considered, especially when/if ADE will be observed 291

Although ADE has yet to be fully observed for SARS-CoV-2 infection or vaccination, 293 previous coronavirus vaccine candidates were reported to be complicated by ADE. A viral vector 294 vaccine of the original SARS was found to enhance the immunopathology of immunized animals 295 following viral challenge, resulting in a strong inflammatory response and even lung injury 53,54 . 296

Mice immunized by Ad5 viral vector expressing MERS vaccine were also reported to exhibit 297 pulmonary pathology following viral challenge, despite the vaccine conferring protection 55 . 298

Similar observation was reported for inactivated virus vaccine. Lung immunopathology was 299 observed when animals were immunized with inactivated whole-virus MERS vaccine, followed 300 by virus challenge 56 . One strategy to offset ADE concern of Dengue and Zika vaccines is to reduce 301 cross-reactive antibody response 57 . Similarly, we used adjacent spike proteins on NP to sterically 302 block the S2 subunit exposure, which was validated with evidence of less S2 subunit and cross- Neutralization assays using above SARS-CoV-2 pseudotyped VSV were performed as 375 previously described 65 with modification. This pseudovirus was first titrated with duplicate on 376

Vero E6 cells cultured in EMEM supplemented with 10% fetal bovine serum and 100 I.U./mL 377 penicillin and 100 μg/mL streptomycin at 37°C. The dilution of pseudovirus to achieve 1,000-fold 378 luciferase signal higher than background was selected for neutralization assay. In neutralization assay, the heat-inactivated serum starting from 100-fold dilution with serial dilutions was 380 incubated with diluted pseudotyped virus in EMEM for 1 hour at 37°C before infecting Vero E6 381 cells at 37°C, 5% CO2 for 1 hour. The next day, cells were lysed with Passive Lysis Buffer 382 

The amounts of RNA copies per gram tissue were measured using a qRT-PCR assay as described 412 previously 34 . Briefly, viral RNA was extracted from lung and nares collected on 7 dpi with RNA-413 STAT 60 (Tel-test"B")/chloroform, precipitated and resuspended in AVE Buffer (Qiagen). To 414 generate a control for the amplification reaction, RNA was isolated from the applicable virus stock 415 using the same procedure. RT-PCR assays were performed using TaqMan RT-PCR kit (Bioline, 416 BIO-78005) with primers and probe sequences described previously 34 . The signal was compared 417 to the known standard curve and calculated to give copies per gram (g). All samples were tested 418 in triplicate. 419

SARS-CoV-2 subgenomic mRNA (sgRNA) was determined as described previously 34 with 421 modification. Briefly, above extracted RNA was first reverse-transcribed using Superscript III 

Severity Grading Scale

The severity of the non-neoplastic tissue lesions is graded as follows:

Grade 1 (1+): Minimal. This corresponds to a histopathologic change ranging from inconspicuous to 652 barely noticeable but so minor, small, or infrequent as to warrant no more than the least assignable grade.

For multifocal or diffusely-distributed lesions, this grade was used for processes where less than 654 approximately10% of the tissue in an average high-power field was involved. For focal or diffuse 655 hyperplastic/hypoplastic/ atrophic lesions, this grade was used when the affected structure or tissue had 656 undergone a less than approximately 10% increase or decrease in volume.

Grade 2 (2+) Mild. This corresponds to a histopathologic change that is a noticeable but not a prominent The neutralizing activity of sera collected at days 14 and 28 against VSV pseudotyped virus with SARS-CoV-2 spike protein containing D614G mutation. NAb titer (neutralizing antibody) represents the reciprocal of the antiserum dilution at which virus entry is inhibited by 50%, when calculated after curve-fitting with the Prism program (GraphPad). Black bars reflect mean responses. Statistical analysis was performed with Mann-Whitney test (* p<0.05). (E) The correlate of serum neutralizing titer and ELISA titer of binding to RBD protein (left) or trimeric spike (right). The correlation for day 14 sera between neutralizing titer (log10) and ELISA binding titer (log10) was analyzed using Spearman nonparametric test. Line represents the best fit linear regression. 

Novel coronavirus: where we are and what we know

Cryo-electron microscopy structure of a coronavirus spike glycoprotein 463 trimer

Tectonic conformational changes of a coronavirus spike glycoprotein 465 promote membrane fusion

Potent neutralizing antibodies from COVID-19 patients define 468 multiple targets of vulnerability

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection 471 from disease in a small animal model

Broad neutralization of SARS-related viruses by human monoclonal 474 antibodies

Convergent antibody responses to SARS-CoV-2 in convalescent 476 individuals

Studies in humanized mice and convalescent humans yield a SARS-CoV-478 2 antibody cocktail

A neutralizing human antibody binds to the N-terminal domain of the Spike 480 protein of SARS-CoV-2

Role of Multivalency and Antigenic Threshold in Generating 482

Nanoparticle Vaccines Adopting 485 Virus-like Features for Enhanced Immune Potentiation

Explanations for the high potency of HPV prophylactic vaccines

Advancing an HIV vaccine; advancing vaccinology

HIV-1 broadly neutralizing antibody precursor B cells revealed by 492 germline-targeting immunogen

Two-component spike nanoparticle vaccine protects macaques 495 from SARS-CoV-2 infection

Elicitation of Potent Neutralizing Antibody Responses by Designed 498 Protein Nanoparticle Vaccines for SARS-CoV-2

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 501 immunogenicity in baboons and protection in mice

NVX-CoV2373 vaccine protects cynomolgus macaque upper 504 and lower airways against SARS-CoV-2 challenge

Hemagglutinin-stem nanoparticles generate heterosubtypic 507 influenza protection

Self-assembling influenza nanoparticle vaccines elicit broadly 509 neutralizing H1N1 antibodies

Approaching rational epitope vaccine design for hepatitis C virus with meta-511 server and multivalent scaffolding

Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles 513 improves their immunogenicity

Presenting native-like trimeric HIV-1 antigens with self-assembling 516 nanoparticles

Rational Design of an Epstein-Barr Virus Vaccine Targeting the 518 Receptor-Binding Site

A single immunization with spike-functionalized ferritin vaccines 520 elicits neutralizing antibody responses against SARS-CoV-2 in mice. bioRxiv

SARS-CoV-2 spike-protein D614G mutation increases virion spike density 523 and infectivity

Spike mutation D614G alters SARS-CoV-2 fitness

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases 528 Infectivity of the COVID-19 Virus

Cryo-EM structure of the 2019-nCoV spike in the prefusion 531 conformation

A noncompeting pair of human neutralizing antibodies block COVID-19 533 virus binding to its receptor ACE2

A human neutralizing antibody targets the receptor-binding site of SARS-536

Human monoclonal antibody combination against SARS coronavirus: 538 synergy and coverage of escape mutants

Ad26 vaccine protects against SARS-CoV-2 severe clinical disease 541 in hamsters

REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus 543 macaques and hamsters

SARS-CoV-2 infection protects against rechallenge in rhesus 545 macaques

Qualitative and 547 quantitative analysis of nonneoplastic lesions in toxicology studies. Toxicologic 548 pathology

Use of Severity Grades to Characterize Histopathologic Changes

Pathogenesis of COVID-19 from a cell biology perspective

Pathogenesis and transmission of SARS-CoV-2 in golden hamsters

A single dose of recombinant VSV-G-spike vaccine provides 556 protection against SARS-CoV-2 challenge

Is COVID-19 receiving ADE from other coronaviruses?

Prevalence of antibodies to four 561 human coronaviruses is lower in nasal secretions than in serum

Age-Related Morbidity and Mortality among Patients with COVID-564 19

Human coronavirus in young children hospitalized for acute respiratory 566 illness and asymptomatic controls

Coronavirus reinfections: three questions scientists are asking

Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy

Modified mRNA Vaccines Protect against Zika Virus Infection

Dengue Virus Serotype 2 Replication In Vitro

Specificity, cross-reactivity, and function of antibodies elicited by Zika 578 virus infection

Analysis of Serologic Cross-Reactivity Between Common Human 580 Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen Microarray. bioRxiv

Cross-reactive serum and memory B cell responses to spike protein in 583 SARS-CoV-2 and endemic coronavirus infection. bioRxiv

Neutralizing and cross-reacting antibodies: 586 implications for immunotherapy and SARS-CoV-2 vaccine development

Immunization with modified vaccinia virus Ankara-based 589 recombinant vaccine against severe acute respiratory syndrome is associated with 590 enhanced hepatitis in ferrets

Anti-spike IgG causes severe acute lung injury by skewing macrophage 593 responses during acute SARS-CoV infection

A Highly Immunogenic, Protective, and Safe Adenovirus-Based 596

Vaccine Expressing Middle East Respiratory Syndrome Coronavirus S1-CD40L Fusion 597 Protein in a Transgenic Human Dipeptidyl Peptidase 4 Mouse Model

Immunization with inactivated Middle East Respiratory Syndrome 600 coronavirus vaccine leads to lung immunopathology on challenge with live virus

Modified mRNA Vaccines Protect against Zika Virus Infection

mRNA-1273 vaccine induces neutralizing antibodies against spike mutants 605 from global SARS-CoV-2 variants. bioRxiv

Stabilized coronavirus spikes are resistant to conformational 607 changes induced by receptor recognition or proteolysis

Immunogenicity and structures of a rationally designed prefusion 610 MERS-CoV spike antigen

Efficient generation of monoclonal antibodies from single human B cells 613 by single cell RT-PCR and expression vector cloning

High-Resolution Longitudinal Study of HIV-1 Env Vaccine-Elicited B Cell 616 Responses to the Virus Primary Receptor Binding Site Reveals Affinity Maturation and 617 Clonal Persistence

HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response 619 Elicited by Immunization in Nonhuman Primates

Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus 622 Fusion Loop as a Site of Vulnerability

Prominent Neutralizing Antibody Response Targeting the Ebolavirus 625

Glycoprotein Subunit Interface Elicited by Immunization

Structural analysis of full-length SARS-CoV-2 spike protein from an 628 advanced vaccine candidate

Topology representing network enables highly accurate 631 classification of protein images taken by cryo electron-microscope without masking

Best practices guideline: toxicologic histopathology

International harmonization of toxicologic pathology nomenclature: an 636 overview and review of basic principles

Proliferative and nonproliferative lesions of the rat and mouse 639 respiratory tract